Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240849 | 0.83 | NNMT (0.54) | MAPTNNMTRAB9A | |
| SCHEMBL4240845 | 0.83 | NNMT (0.54) | MAPTNNMTRAB9A | |
| SCHEMBL8309216 | 0.81 | MAPT (0.60) | MAPTDGAT1NNMTL3MBTL1USP2 | |
| SCHEMBL11776067 | 0.75 | USP2 (0.54) | MAPTUSP2RAB9A | |
| SCHEMBL11776061 | 0.75 | USP2 (0.54) | MAPTUSP2RAB9A | |
| SCHEMBL17394883 | 0.75 | MAPT (0.37) | MAPT | |
| SCHEMBL17394884 | 0.75 | MAPT (0.37) | MAPT | |
| SCHEMBL796493 | 0.74 | MAPT (1.00) | MAPTNNMTL3MBTL1 | |
| SCHEMBL1092552 | 0.74 | MAPT (0.74) | MAPTNNMTL3MBTL1CXCR1CXCR2 | |
| SCHEMBL4491812 | 0.73 | HDAC1 (0.47) | MAPTDGAT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| WO-2020165062-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, TNNI3K, CILK1 | MAPT 3800/4885DGAT1 4611/4885NNMT 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.